Bishnu Subedi
'Why we do What we do in Cardiology'Episodes
Best Episodes of 'Why we do What we do in Cardiology'
Mark All
Search Episodes...
1. The REDUCE-AMI trial showed no significant benefit of beta-blockers in reducing all-cause mortality or future myocardial infarction in patients with acute myocardial infarction and preserved left ventricular ejection fraction.2. The trial i
The HF-OPT study investigated the improvement of left ventricular ejection fraction (LVEF) beyond 90 days in patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF).In this prospective, multicenter observational stud
Overview: This review discusses the use and future directions of AI in cardiology, focusing on areas like electrocardiography, telemetry and wearables, echocardiography, CMR, nuclear cardiology, CT, electrophysiology studies, coronary angiogr
Collaborative vascular care is emphasized to address health disparities, gaps in medical therapy, structured exercise, and good foot care along with appropriate revascularization to prevent limb loss.The new guidelines update the 2016 guid
2024 HCM Guidelines Focus on Cardiac Myosin Inhibitors and ExerciseMavacamten: Class 1 recommendation for symptomatic obstructive HCM.Exercise: Now allows for "vigorous" activity; competitive level still limited.Pediatric Section: Separ
Key Points: Positive Aspects of DOACs: DOACs are acknowledged for their convenience, efficacy, and safety in conditions like atrial fibrillation (AF) and venous thromboembolism (VTE). The review supports their use in stroke prevention, AF, re
Background: Traditional practice requires fasting before cardiac catheterization, but there's no evidence to support it.Objective: This study compared a heart-healthy pre-procedure diet with fasting to determine best practices.Methods: 197 pa
Key PointsIn patients not taking antianginal meds, PCI alleviated some—but not all—symptomsBackground:Percutaneous coronary intervention (PCI) is commonly used to alleviate stable angina symptoms.Uncertainty exists regarding whether PCI
Study: STRONG-HF trial examined rapid up-titration of heart failure medications (GDMT) after hospitalization.Goal: Reach optimal GDMT doses within 2 weeks after discharge.Findings:Over 90% of patients achieved medium-to-high GDMT doses withi
Key Points from "Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR":The study compares two strategies for managing LDL cholesterol in coronary artery disease (CAD):Treat-to-target: aiming for LDL levels between 50-70 m
Key Points of the Study:T-TEER with the TriClip device significantly improved health status in patients with severe tricuspid regurgitation (TR) compared to medical therapy alone.This improvement was seen in both the short-term (1 month) and
Key Points from PROMISE 2 Trial:• Problem: 20% of CLTI patients have no revascularization options, leading to amputations.• Solution: Transcatheter arterialization of deep veins creates an artery-to-vein connection, delivering oxygenated bloo
Key Points from this trial:The CLASP IID trial, the first randomized controlled trial comparing the PASCAL system and the MitraClip system in prohibitive-risk patients with significant symptomatic degenerative mitral regurgitation (DMR), aime
Key points of the DANPACE II study on atrial pacing and atrial fibrillation in sinus node dysfunction:1. Minimizing atrial pacing in pacemakers doesn't prevent atrial fibrillation (AF):• 46% of patients regardless of pacing rate (40bpm or 60b
Major Trends:Independent Medical Board: Cardiologists seek a new board separate from the ABIM due to concerns with MOC requirements.Scope of Practice Debates: Tensions arise over advanced nurse practitioners performing complex procedures l
Key Points of Coronary Artery Disease Studies in 2023:• ORBITA-2: Confirmed PCI's role in relieving angina symptoms for stable patients.• SELECT: Semaglutide (Ozempic) reduced cardiovascular events in overweight/obese patients with existing C
A quick rundown of the key developments:Trials:STEP-HFpEFCASTLE-HTxHEART FIDDAPA-MIPolicy and Guidelines:ESC cardiomyopathy guidelinesInflation Reduction ActFDA approvals: dapagliflozin and sotagliflozinOther Highlight
Focus on Valves:TAVI vs. SAVR: Long-term data showed mixed results. PARTNER 3 (Sapien 3 valve) benefits declined over time, while Evolut Low Risk (CoreValve, Evolut R/PRO) favoured TAVI. Experts advise caution in direct comparison.Aortic R
Key Highlights:Lodoco is the first anti-inflammatory approved for reducing cardiovascular events in ASCVD patients.Bempedoic acid offers an alternative for high-risk patients who can't tolerate statins.Semaglutide has emerged as a powerf
Key Points of Endovascular Procedures and Devices in 2023:FDA Actions:Lifted restrictions on paclitaxel-coated balloons and stents for PAD after updated data showed no increased mortality risk.Approved coverage of carotid artery stenting
Heart Rhythm 2023: Innovations in Ablation, Devices, and Conduction System Pacing.Catheter Ablation and LAAO Advance:CASTLE-HTx: Ablation for AF proved beneficial in patients with advanced heart failure, potentially paving the way for wide
Key Points:Multi-vessel coronary disease (MVD) in acute myocardial infarction (AMI) is still a difficult condition to manage.Complete revascularization improves outcomes for hemodynamically stable patients without any safety concerns.A p
Key findings of the FRAIL-AF trial: * Switching from vitamin K antagonist (VKA) to non-vitamin K antagonist oral anticoagulant (NOAC) therapy was associated with an increased risk of major and clinically relevant bleeding (hazard ratio [HR] 1
Summary of the STEP-HFpEF trial 2023 published in Nature MedicineThe STEP-HFpEF trial was a study of semaglutide in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF).Semaglutide improved symptoms, phy
Key points of the FIRE trial: The study was a randomized trial of complete revascularization vs. culprit-only revascularization in older patients (≥75 years of age) with myocardial infarction and multi-vessel disease.A total of 1445 patie
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us